Author

M. C. Mariano

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:proteomics· 3 Approach:statistical model· 3 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1

Frequent Co-Authors

A. P. Wiita· 3 shared I. D. Ferguson· 3 shared Y.-H. T. Lin· 3 shared C. Driessen· 2 shared A. M. Thornton· 1 shared A. N. Brooks· 1 shared B. C. Hann· 1 shared B. G. Barwick· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. P. Wiita

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivApr 21, 2020

Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma

I. D. Ferguson, Y.-H. T. Lin, C. Lam…·A. P. Wiita

This study identifies allosteric HSP70 inhibitors that overcome proteasome inhibitor resistance in multiple myeloma by targeting mitochondrial HSPA9 and disrupting mitoribosome stability.

DOI 10.1016/j.chembiol.2022.06.010

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivFeb 28, 2019

Integrated Phosphoproteomics and Transcriptional Classifiers Reveal Hidden RAS Signaling Dynamics in Multiple Myeloma

Y.-H. T. Lin, G. P. Way, B. G. Barwick…·A. P. Wiita

The paper uses phosphoproteomics and transcriptomics to analyze RAS signaling in multiple myeloma, identifying distinct signaling patterns and clinical outcomes associated with NRAS and KRAS mutations.

DOI 10.1182/bloodadvances.2019000303

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivFeb 3, 2019

Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma

H. H.-L. Huang, I. D. Ferguson, A. M. Thornton…·A. P. Wiita

The paper shows proteasome inhibitors modulate splicing in multiple myeloma, revealing spliceosome inhibition as a therapeutic target.

DOI 10.1038/s41467-020-15521-4

humanproteomics

𝕏 PostBluesky